Press Releases

Date Title and Summary View
Toggle Summary MediWound to Present at Upcoming Investor Conferences
YAVNE, Israel , Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management will present at the following
View HTML
Toggle Summary MediWound Reports Second Quarter Financial Results
Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year Positive Interim Assessment Outcome for EscharEx U.S. Phase II Clinical Study No Changes to Study Sample Size – No Safety Concerns Identified Conference call begins today at 8:30 am ET   YAVNE, Israel , Aug.
View HTML
Toggle Summary MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021
YAVNE, Israel , Aug. 02, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the second
View HTML
Toggle Summary MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study
Independent Data Monitoring Committee R ecommends C ontinuation of the Study with N o   C hanges to Study Sample Size No Safety Concerns Identified Full Study   Enrollment Expected by Year-End 2021; D ata R eadout E xpected in t he F irst H alf of 2022 YAVNE, Israel , July 28, 2021 (GLOBE NEWSWIRE)
View HTML
Toggle Summary MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
Data Expected End of 2021 Phase II Investigator-Initiated Trial in Non-Melanoma Skin Cancers Running in Parallel YAVNE, Israel , July 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for
View HTML
Toggle Summary MediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns
Primary Endpoints Met with Highly Statistically Significant Results Compared with Standard-of-Care YAVNE, Israel , July 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair
View HTML
Toggle Summary MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal
Study Findings D emonstrate S trong R esults in Debriding V enous L eg U lcers and   D iabetic F oot U lcers Interim Assessment of Ongoing U.S.   Phase II Adaptive Design Study in Venus Leg Ulcers Expected End of July 2021 YAVNE, Israel , July 09, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd.
View HTML
Toggle Summary MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application
Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy YAVNE, Israel , June 29, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair
View HTML
Toggle Summary MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study
Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021 YAVNE, Israel , June 09, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and
View HTML
Toggle Summary MediWound Announces Peer-Reviewed Paper of a Case Series Report of Basal Cell Carcinoma Published in the Open Dermatology Journal
Findings Provide Preliminary Proof-of-Concept Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin in Second Quarter 2021, with Data Expected by the End of 2021 YAVNE, Israel , June 07, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical
View HTML